Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 19/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181744 | 0.81 | ALDH1A1 (0.34) | MGLL | |
| SCHEMBL45664 | 0.81 | ALDH1A1 (0.34) | MGLL | |
| SCHEMBL20057216 | 0.81 | MGLL (0.40) | MGLL | |
| SCHEMBL23760484 | 0.80 | ALDH1A1 (0.33) | — | |
| SCHEMBL10105716 | 0.80 | ALDH1A1 (0.33) | — | |
| SCHEMBL28059247 | 0.78 | — | — | |
| SCHEMBL12261667 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL9441056 | 0.77 | GSK3B (0.37) | — | |
| SCHEMBL20253903 | 0.77 | BACE1 (0.38) | MGLL | |
| SCHEMBL20057040 | 0.77 | BACE1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449258-B2 | Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-3308801-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2018-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10449258-B2 | Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof | FCGR3B, SI, INCENP | MGLL 2885/4885 |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | FCGR3B, SI, INCENP | MGLL 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.